Citidaron Tolerability
Citidaron® Tolerability1
Mild to moderate adverse reactions have been observed with the use of Citidaron®, most frequently concerning the gastrointestinal tract.
Clinical trials and prior experience indicate that the majority of
adverse reactions occurred at the beginning of
Citidaron® therapy and resolved during treatment.
The following more frequently noted adverse events were observed in clinical trials.
| Adverse Event Class | Very Common (1/10) | Common (1/100 to >1/100) |
|---|---|---|
| Metabolism and nutrition disorders | Change in appetite (mainly increase), weight gain | |
| Nervous system disorders | Dizziness, irritably, mood changes, anxiety, sleep disorders, (insomnia, drowsiness, lethargy, abnormal dreams, nightmares) headaches | Difficulty in concentration |
| Cardiac disorders | Tachycardia | Slow heart rate |
| Vascular disorders | Hypertension | |
| Gastrointestinal disorders | Dry mouth, diarrhoea, nausea, changes flavour, heartburn, constipation, vomiting, abdominal pain (especially in the upper abdomen) | Abdominal distension burning tongue |
| Skin and subcutaneous tissue disorders | Rash | |
| Musculoskeletal and connective tissues disorders | Myalgia | |
| General disorders and administration site conditions | Fatigue | Malaise |
References
- CITIDARON® Summary of Product Characteristics, Consilient Health 2025.
Safety Profile
Get an overview of the safety data and tolerability of Citidaron.
Taking Citidaron
See the step-by-step course for taking Citidaron
Resources for you
Find additional support and information to help your patients succeed
Adverse events should be reported. Reporting forms and information are available from HPRA Pharmacovigilance on the HPRA website www.hpra.ie. Adverse events should also be reported to Consilient Health at drugsafety@consilienthealth.com or 012057766.
The information on this website is intended for Health Care Professional who practice in the Republic of Ireland only
Sign up to stay informed about upcoming webinars
IE-CH-1732(1), March 2026